Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275279 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1CA14CA12KMT2A | |
| SCHEMBL28458338 | 0.76 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1CA14 | |
| SCHEMBL11143577 | 0.75 | SMN1; SMN2 (0.34) | SMN1; SMN2CA14 | |
| SCHEMBL2727651 | 0.74 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1CA14CA12KMT2A | |
| SCHEMBL276322 | 0.74 | KMT2A (0.43) | SMN1; SMN2ALDH1A1CA14CA12KMT2A | |
| SCHEMBL2289696 | 0.72 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1CA14CA12KMT2A | |
| SCHEMBL13943337 | 0.72 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1CA14CA12KMT2A | |
| SCHEMBL5840367 | 0.72 | SMN1; SMN2 (0.40) | SMN1; SMN2ALDH1A1CA14CA12KMT2A | |
| SCHEMBL5143818 | 0.72 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1CA14CA12KMT2A | |
| SCHEMBL23028852 | 0.70 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1CA14CA12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785462-B2 | 5-hydroxypyrimidine-4-carboxamide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20120220609-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-0965589-B1 | Process and intermediates for the manufacture of pyridine-2,3-dicarboxylate compounds | BASF AG (DE) | 2004-12-08 | — | — | EP | disclosed |
| EP-0965589-A1 | Process and intermediates for the manufacture of pyridine-2,3-dicarboxylate compounds | American Cyanamid Company (US) | 1999-12-22 | — | — | EP | disclosed |
| US-5925764-A | CONDENSATION OF AMINOMALEATE ESTERS WITH ACROLEIN DERIVATIVE TO FORM PYRIDINE-2,3-DICARBOXYLATE COMPOUNDS | BASF AKTIENGESELLSCHAFT | 1999-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220609-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | EPOR, EGLN2, EGLN1 | SMN1; SMN2 3094/4885ALDH1A1 388/4885CA14 4432/4885 |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | EPOR, CBR1, CBR3 | SMN1; SMN2 2425/4885ALDH1A1 1179/4885CA14 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.